Indian pharmaceutical stocks tumbled 4.4% on Friday, erasing gains from the previous session, after Trump threatened steep ...

Shares of Indian pharma companies, including Aurobindo Pharma, Laurus Labs, IPCA Labs, and Lupin, fell up to 8% after U.S.

Indian drugmakers relieved as Trump exempts pharmaceuticals from tariffs, highlighting critical role of generic medicines in ...

Indian stock markets opened flat on Friday, striking a balance between the bear and bull gangs in the market. The Nifty 50 ...

India’s benchmark indices, Sensex and Nifty50, opened almost flat on Friday, March 28, 2025. More details inside!

Cipla faces headwinds but remains resilient with strong product portfolio, robust earnings growth potential, and reasonable ...

India is on track to exceed 1 billion tonnes of coal production in the current financial ... power demand has already begun to rise in several regions and is expected to increase further as ...

Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain following ocular surgery across 11 countries such as India, Nepal, Sri ...

Under the terms of the agreement, Cipla has exclusive rights to market APP13007 across 11 countries: India, Nepal, Sri Lanka, Bangladesh, Malaysia, Myanmar, Kenya, Nigeria, South Africa, Argentina, ...

View a comprehensive summary of the Cipla share, providing essential insights into its performance. Signals range from Strong Buy, Buy, Neutral, Sell, to Strong Sell, helping gauge the stock's ...

Incentivized by robust demand, developers in India continue to prioritize high-end properties, with the luxury segment now driving the overall market growth; the availability of affordable housing ...

The automotive sector, for example, has seen tremendous growth, with India becoming one of the largest producers of vehicles in the world. Multinational companies such as Toyota, Hyundai, and General ...